Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00580775 · ClinicalTrials.gov registry record
Study of Early Hormone Replacement Therapy on Risk Factors for Sudden Cardiac Death
A clinical trial, sponsored by Yale University.
- Completed
- Registry status
- 25
- Enrollment target
NCT00580775: Completed study, sponsored by Yale University.
NCT00580775 is a clinical trial that has completed, run by Yale University. The registered enrollment target is 25 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00580775 has completed, sponsored by Yale University.
- COMPLETED
- Registry status
- 25 participants
- Enrollment target
Study Summary
As an ancillary study to the KEEPS study (see ClinicalTrials.gov Identifier: NCT00154180), the primary purpose is to measure effects of estrogen vs. placebo in menopausal women, on autonomic function and repolarization; both measured non-invasively via holter monitoring.
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 25 participants |
| Start Date | 2005-09 |
| Est. Completion | 2010-12 |
What the finished NCT00580775 record still lists
NCT00580775 is an observational study that tracks outcomes without assigning an intervention. The registry caps enrollment at 25 participants, a relatively small participant target.
The record links to 0 conditions, and to 0 interventions.
NCT00580775 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT00580775 about?
NCT00580775 is a clinical study titled "Study of Early Hormone Replacement Therapy on Risk Factors for Sudden Cardiac Death". As an ancillary study to the KEEPS study (see ClinicalTrials.gov Identifier: NCT00154180), the primary purpose is to measure effects of estrogen vs. placebo in menopausal women, on autonomic function and repolarization; both measured non-invasively via holter monitoring.
What is the current status of trial NCT00580775?
This trial is currently completed. The enrollment target is 25 participants. The study started on 2005-09. Estimated completion is 2010-12.
Who is sponsoring clinical trial NCT00580775?
This trial is sponsored by Yale University, which has 1,492 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT01166854 · 25 participants
Characterization of Familial Myopathy and Paget Disease of Bone
- NCT01913106 · 25 participants · Phase 1
HSV-tk + Valacyclovir Therapy in Combination With Brachytherapy for Recurrent Prostate Cancer
- NCT02138669 · 25 participants · NA
Intacs Prescription Inserts for Keratoconus Patients
- NCT02174549 · 25 participants · Phase 1
Dose-defining Study of Tirapazamine Combined With Embolization in Liver Cancer
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia